Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

At the start of this year, Ed­i­tas Med­i­cine nar­rowed its pipeline and laid off 20% of its work­force, a move to save cash and fo­cus on its gene-edit­ed cell ther­a­py can­di­date ED­IT-301 for sick­le cell dis­ease and trans­fu­sion-de­pen­dent be­ta tha­lassemia.

Now the com­pa­ny has da­ta from a hand­ful of pa­tients to show for it, it an­nounced Fri­day.

In the com­pa­ny’s the Phase I/II RU­BY tri­al, Ed­i­tas re­port­ed da­ta for the first four pa­tients with sick­le cell dis­ease treat­ed with ED­IT-301, two of whom reached nor­mal he­mo­glo­bin lev­els five months af­ter treat­ment. Both pa­tients al­so main­tained nor­mal he­mo­glo­bin lev­els at check­ups 10 and six months af­ter treat­ment and had a lev­el of fe­tal he­mo­glo­bin greater than 40% dur­ing the same time frame.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN